GnRH Agonist for Infertility
Trial Summary
Do I have to stop taking my current medications for this trial?
The trial protocol does not specify whether you need to stop taking your current medications.
What data supports the idea that GnRH Agonist for Infertility is an effective treatment?
The available research shows that GnRH agonists are effective in improving pregnancy and live birth rates, especially in women with polycystic ovary syndrome (PCOS) undergoing in vitro fertilization (IVF). They are used in a 'long protocol' before other fertility drugs, which has consistently shown better outcomes. However, GnRH antagonists, a different type of treatment, are becoming more popular because they offer similar success rates with shorter treatment times and fewer side effects. This suggests that while GnRH agonists are effective, there might be more convenient alternatives available.12345
What safety data is available for GnRH agonists used in infertility treatment?
GnRH agonists, also known by names like LHRH and Gonadorelin, have been studied primarily in the context of prostate cancer treatment. Some studies suggest they may have a higher risk of adverse events compared to other therapies, such as antiandrogens or GnRH antagonists, particularly concerning cardiovascular risks. However, these findings are not consistent across all studies. In terms of fertility treatments, GnRH antagonists have been shown to be safe with no adverse effects on offspring in animal studies, and careful study of pregnancy outcomes in humans is recommended. Overall, GnRH analogues are considered safe and effective in clinical settings, though they may have specific safety considerations like initial flare-ups in prostate cancer treatment.678910
Is the drug used in the trial titled 'GnRH Agonist for Infertility' a promising treatment?
Yes, the drug used in the trial is promising for treating infertility. GnRH agonists help control ovarian stimulation, which is important in assisted reproductive technology. They have shown positive results in improving pregnancy outcomes and are considered valuable in reproductive treatments.311121314
What is the purpose of this trial?
During IVF cycles an embryo is generally placed into the uterine cavity between 3 and 5 days after fertilization. For a successful pregnancy to take place, that embryo must then implant in the properly primed and staged endometrium, which subsequently must continue to develop to accommodate the growing and maturing embryo and then fetus. This process is normally regulated by hormonal interactions between the fetal, endometrial and luteal tissue. It has been found that after IVF additional support for the endometrium with progesterone improves implantation and subsequent live birth rates in IVF cycle . Recent data has shown that additional supplementation with a single administration of a GnRH agonist around the time the time of embryo transfer may further enhance these rates .
Research Team
Peter G McGovern, MD
Principal Investigator
Rutgers University
Eligibility Criteria
This trial is for women under 40 years old undergoing IVF, ICSI, or frozen embryo transfers to help with infertility. It's not for those having an embryo transfer on day 3 of the process.Inclusion Criteria
Exclusion Criteria
Timeline
Screening
Participants are screened for eligibility to participate in the trial
Treatment
Participants receive either a GnRH agonist or placebo around the time of embryo transfer to support endometrial development
Follow-up
Participants are monitored for implantation success and pregnancy outcomes
Treatment Details
Interventions
- GnRH
Find a Clinic Near You
Who Is Running the Clinical Trial?
University Reproductive Associates
Lead Sponsor